サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1761125

ウイルスベクター製造の世界市場

Viral Vector Manufacturing

出版日
ページ情報
英文 402 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.66円
ウイルスベクター製造の世界市場
出版日: 2025年07月02日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 402 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ウイルスベクター製造の世界市場は2030年までに26億米ドルに達する見込み

2024年に9億5,360万米ドルと推定されるウイルスベクター製造の世界市場は、分析期間2024-2030年にCAGR 18.3%で成長し、2030年には26億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるレトロウイルスベクターは、CAGR18.1%を記録し、分析期間終了時には9億5,460万米ドルに達すると予測されます。アデノウイルスベクターセグメントの成長率は、分析期間中CAGR18.6%と推定されます。

米国市場は5億6,900万米ドルと推定、中国はCAGR21.3%で成長すると予測

米国のウイルスベクター製造市場は、2024年に5億6,900万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億790万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは21.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、それぞれ分析期間中に15.6%と15.1%のCAGRで成長すると予測されています。欧州では、ドイツがCAGR約14.5%で成長すると予測されています。

世界のウイルスベクター製造市場- 主要動向と促進要因まとめ

ウイルスベクター製造は、遺伝子治療、ワクチン開発、がん治療の分野で重要なプロセスであり、細胞内に遺伝物質を送達するように設計されたウイルスの生産を伴う。これらのベクターは、アデノウイルス、レンチウイルス、アデノ随伴ウイルス（AAV）に由来することが多く、遺伝子の欠損を修正したり、免疫反応を誘発したり、がん細胞を破壊したりする治療遺伝子を導入するために使用されます。ウイルスベクターの製造は複雑で高度に規制されたプロセスであり、特殊な設備、厳格な品質管理、適正製造規範（GMP）の遵守を必要とします。製造プロセスには、ベクターの設計、上流の製造（細胞培養とウイルス増幅）、下流の処理（精製と濃縮）、そしてウイルスベクターの安全性、力価、純度を保証するための最終的な製剤化と品質試験など、いくつかの段階が含まれます。

ウイルスベクター製造の動向は、技術と生産能力における著しい進歩を浮き彫りにしています。バイオリアクター設計と細胞培養技術の革新は、ウイルスベクター生産のスケーラビリティと効率を向上させました。シングルユース・バイオリアクターと連続製造プロセスは、生産を合理化し、汚染リスクを低減するために、ますます採用されるようになっています。さらに、クロマトグラフィーやろ過などの精製技術の進歩により、ウイルスベクターの収量と品質が向上しています。自動化とリアルタイム・モニタリング・システムの統合により、製造工程はさらに最適化され、より一貫した再現性の高いベクター生産が可能となっています。また、臨床および商業用途におけるウイルスベクターの需要の高まりに対応するため、費用対効果に優れ、スケーラブルなソリューションの開発が重視されるようになってきています。学術機関、バイオテクノロジー企業、製造受託機関（CMO）のコラボレーションが技術革新を推進し、ウイルスベクター生産の世界の能力を拡大しています。

ウイルスベクター製造市場の成長は、いくつかの要因によって牽引されています。遺伝性疾患の有病率の増加と臨床開発中の遺伝子治療のパイプラインの拡大が、ウイルスベクターの需要を大幅に押し上げています。LuxturnaやZolgensmaなどの遺伝子治療の成功やCAR-T細胞治療の承認は、以前は難治性であった疾患の治療におけるウイルスベクターの可能性を実証し、この分野へのさらなる投資と研究を促しています。COVID-19パンデミックはまた、ワクチン開発におけるウイルスベクターの重要性を浮き彫りにし、ジョンソン・エンド・ジョンソンやアストラゼネカが開発したワクチンを含むいくつかのワクチンがウイルスベクター技術を利用しています。さらに、ベクター工学と製造技術の進歩により、製造プロセスの効率性と拡張性が向上し、ウイルスベクター療法がより利用しやすく、費用対効果の高いものとなっています。政府機関や民間投資家からの規制支援や資金提供は、市場の成長をさらに後押ししています。バイオテクノロジー企業、学術機関、CMO間の協力や提携の増加は、製造能力を拡大し、ウイルスベクターベースの治療法の開発と商業化を加速しています。これらの要因が相まって、ウイルスベクター製造市場の堅調な成長が保証され、継続的な技術革新が促進され、さまざまな治療用途に広く採用されるようになっています。

セグメント

タイプ（レトロウイルスベクター、アデノウイルスベクター、アデノ随伴ウイルスベクター、その他のタイプ）;疾患（がん、遺伝子疾患、感染症、その他の疾患）;エンドユーザー（製薬・バイオファーマ企業、調査機関）

調査対象企業の例（注目の80社）

  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • Akron Biotech
  • GeneCopoeia, Inc.
  • Aldevron
  • GenScript Biotech Corporation
  • DNA TwoPointO Inc.（dba ATUM）
  • Genelux Corporation
  • Cell and Gene Therapy Catapult
  • ID Pharma Co., Ltd.
  • Global Life Sciences Solutions USA LLC（Cytiva）
  • Algenex
  • BioFactura
  • Delphi Genetics
  • FinVector OY

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中のドメイン専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP15508

Global Viral Vector Manufacturing Market to Reach US$2.6 Billion by 2030

The global market for Viral Vector Manufacturing estimated at US$953.6 Million in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 18.3% over the analysis period 2024-2030. Retroviral Vectors, one of the segments analyzed in the report, is expected to record a 18.1% CAGR and reach US$954.6 Million by the end of the analysis period. Growth in the Adenoviral Vectors segment is estimated at 18.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$569.0 Million While China is Forecast to Grow at 21.3% CAGR

The Viral Vector Manufacturing market in the U.S. is estimated at US$569.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$107.9 Million by the year 2030 trailing a CAGR of 21.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.6% and 15.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.5% CAGR.

Global Viral Vector Manufacturing Market - Key Trends & Drivers Summarized

Viral vector manufacturing is a critical process in the field of gene therapy, vaccine development, and cancer treatment, involving the production of viruses engineered to deliver genetic material into cells. These vectors often derived from adenoviruses, lentiviruses, or adeno-associated viruses (AAVs), are used to introduce therapeutic genes to correct genetic defects, provoke immune responses, or destroy cancer cells. The production of viral vectors is a complex and highly regulated process that requires specialized facilities, stringent quality control, and adherence to good manufacturing practices (GMP). The manufacturing process involves several stages, including vector design, upstream production (cell culture and virus amplification), downstream processing (purification and concentration), and final formulation and quality testing to ensure safety, potency, and purity of the viral vectors.

Trends in viral vector manufacturing highlight significant advancements in technology and production capabilities. Innovations in bioreactor design and cell culture techniques have enhanced the scalability and efficiency of viral vector production. Single-use bioreactors and continuous manufacturing processes are increasingly adopted to streamline production and reduce contamination risks. Additionally, advances in purification technologies, such as chromatography and filtration, have improved the yield and quality of viral vectors. The integration of automation and real-time monitoring systems has further optimized the manufacturing process, allowing for more consistent and reproducible vector production. There is also a growing emphasis on developing cost-effective and scalable solutions to meet the rising demand for viral vectors in clinical and commercial applications. Collaborations between academic institutions, biotech companies, and contract manufacturing organizations (CMOs) are driving innovation and expanding the global capacity for viral vector production.

The growth in the viral vector manufacturing market is driven by several factors. The increasing prevalence of genetic disorders and the expanding pipeline of gene therapies in clinical development have significantly boosted the demand for viral vectors. The success of gene therapies, such as Luxturna and Zolgensma, and the approval of CAR-T cell therapies have demonstrated the potential of viral vectors in treating previously intractable diseases, encouraging further investment and research in this field. The COVID-19 pandemic also underscored the importance of viral vectors in vaccine development, with several vaccines, including those developed by Johnson & Johnson and AstraZeneca, utilizing viral vector technology. Additionally, advancements in vector engineering and manufacturing technologies have enhanced the efficiency and scalability of production processes, making viral vector therapies more accessible and cost-effective. Regulatory support and funding from government agencies and private investors are further propelling market growth. The increasing collaborations and partnerships between biotech companies, academic institutions, and CMOs are expanding manufacturing capabilities and accelerating the development and commercialization of viral vector-based therapies. These factors collectively ensure the robust growth of the viral vector manufacturing market, fostering continuous innovation and wider adoption in various therapeutic applications.

SCOPE OF STUDY:

The report analyzes the Viral Vector Manufacturing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors, Other Types); Disease (Cancer, Genetic Disorders, Infectious Diseases, Other Diseases); End-Use (Pharma & Biopharma Companies, Research Institutes)

Geographic Regions/Countries:

World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Rest of Europe; Asia-Pacific; Rest of World.

Select Competitors (Total 80 Featured) -

  • Bayer AG
  • Janssen Pharmaceuticals, Inc.
  • Akron Biotech
  • GeneCopoeia, Inc.
  • Aldevron
  • GenScript Biotech Corporation
  • DNA TwoPointO Inc. (dba ATUM)
  • Genelux Corporation
  • Cell and Gene Therapy Catapult
  • ID Pharma Co., Ltd.
  • Global Life Sciences Solutions USA LLC (Cytiva)
  • Algenex
  • BioFactura
  • Delphi Genetics
  • FinVector OY

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • An Introduction to Viral Vector Manufacturing
    • Applications of Viral Vectors
    • Types of Viral Vectors
    • Global Viral Vector Manufacturing Market: Prospects & Outlook
    • Competition
    • Recent Market Activity
    • Viral Vector Manufacturing - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Infectious Diseases, Genetic Disorders & Cancers Drives Market
    • Global Aging Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050
    • Elderly Population (65+ Years) as a % of Total Population by Developed, Less Developed and Least Developed Regions: 2019 & 2030
    • Life Expectancy at Age 60 and 80 Years: (2010-2015), (2020-2025) & (2045-2050)
    • Gene Therapy Emerges as a Major Therapeutic Approach for Inheritable and Acquired Diseases, Spurring Market Prospects
    • Viral Vectors Lead the Gene Therapy Market
    • Adeno-Associated Virus Vectors: A Leading Platform for Gene Therapy
    • Lentiviral Vectors Witness Increased Interest for Gene Therapy
    • Funding Support for Gene Therapy Development Presents Market Opportunities
    • Complexity in Viral Vector Production for Gene therapies
    • Amidst Rising Cancer Incidence, Focus on Viral Vector-based Gene Therapies to Boost Market
    • Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040
    • Engineered and Natural Oncolytic Viral Vectors: A Key Development in Viral Vector-based Cancer Therapy
    • Growing Threat Posed by Infectious Diseases Drives Focus onto Vector Viral-based Therapies & Vaccines
    • Infectious Diseases Remain Major Cause of Death in Under Developed Regions: Breakdown of Leading Causes of Death in Sub-Saharan Africa (in %)
    • Infectious Diseases Related Mortality High Among Children Below 5 Years: Breakdown of Leading Causes of Death in Children Below 5 Years (in %)
    • Rising Significance of Viral Vectors in New Vaccine Development
    • Adenovirus-based Vaccines: Evolution Over the Years
    • Viral Vector Emerges as a Next-Gen Platform for COVID-19 Vaccines Development
    • Replicating and Non-Replicating Viral Vector-Based Vaccines
    • Market to Benefit from the Emergence of New Technologies to Manufacture Viral Vectors
    • New Trends for Optimizing Workflow Using Viral Vectors
    • Production Workflow & Viral Vectors
    • Closed-System-Adherent Culture of Cells: Recent Advances
    • Limitations in Viral Vector Manufacturing Impact Market
    • Innovations & Collaborations: Essential to Resolve Challenges Facing Large-Scale GMP Viral Vector Manufacturing
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Viral Vector Manufacturing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 3: World 14-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2016, 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Retroviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 6: World 14-Year Perspective for Retroviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Adenoviral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 9: World 14-Year Perspective for Adenoviral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Adeno-associated Viral Vectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 12: World 14-Year Perspective for Adeno-associated Viral Vectors by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 15: World 14-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 18: World 14-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Genetic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 21: World 14-Year Perspective for Genetic Disorders by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 24: World 14-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 27: World 14-Year Perspective for Other Diseases by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Pharma & Biopharma Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 30: World 14-Year Perspective for Pharma & Biopharma Companies by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 33: World 14-Year Perspective for Research Institutes by Geographic Region - Percentage Breakdown of Value Revenues for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2016, 2025 & 2030
    • TABLE 34: World Viral Vector Manufacturing Market Analysis of Annual Sales in US$ Thousand for Years 2016 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 35: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 37: USA 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 40: USA 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 43: USA 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • CANADA
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 46: Canada 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 49: Canada 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 52: Canada 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • JAPAN
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 53: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Japan Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 55: Japan 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 58: Japan 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 61: Japan 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • CHINA
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 62: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 64: China 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 65: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 67: China 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 70: China 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • EUROPE
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Viral Vector Manufacturing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 73: Europe 14-Year Perspective for Viral Vector Manufacturing by Geographic Region - Percentage Breakdown of Value Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2016, 2025 & 2030
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 76: Europe 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 79: Europe 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 82: Europe 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • FRANCE
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 83: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: France Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 85: France 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 86: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 88: France 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 91: France 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • GERMANY
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 92: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Germany Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 94: Germany 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 97: Germany 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 100: Germany 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • ITALY
    • TABLE 101: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Italy Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 103: Italy 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 106: Italy 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 109: Italy 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • UNITED KINGDOM
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 110: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: UK Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 112: UK 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 113: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 115: UK 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 118: UK 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • REST OF EUROPE
    • TABLE 119: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Rest of Europe Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 121: Rest of Europe 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Europe Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 124: Rest of Europe 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 125: Rest of Europe Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Europe Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 127: Rest of Europe 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • ASIA-PACIFIC
    • Viral Vector Manufacturing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Asia-Pacific Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 130: Asia-Pacific 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 131: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Asia-Pacific Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 133: Asia-Pacific 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Asia-Pacific Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 136: Asia-Pacific 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030
  • REST OF WORLD
    • TABLE 137: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of World Historic Review for Viral Vector Manufacturing by Type - Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 139: Rest of World 14-Year Perspective for Viral Vector Manufacturing by Type - Percentage Breakdown of Value Revenues for Retroviral Vectors, Adenoviral Vectors, Adeno-associated Viral Vectors and Other Types for the Years 2016, 2025 & 2030
    • TABLE 140: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of World Historic Review for Viral Vector Manufacturing by Disease - Cancer, Genetic Disorders, Infectious Diseases and Other Diseases Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 142: Rest of World 14-Year Perspective for Viral Vector Manufacturing by Disease - Percentage Breakdown of Value Revenues for Cancer, Genetic Disorders, Infectious Diseases and Other Diseases for the Years 2016, 2025 & 2030
    • TABLE 143: Rest of World Recent Past, Current & Future Analysis for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes - Independent Analysis of Annual Revenues in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of World Historic Review for Viral Vector Manufacturing by End-Use - Pharma & Biopharma Companies and Research Institutes Markets - Independent Analysis of Annual Revenues in US$ Thousand for Years 2016 through 2023 and % CAGR
    • TABLE 145: Rest of World 14-Year Perspective for Viral Vector Manufacturing by End-Use - Percentage Breakdown of Value Revenues for Pharma & Biopharma Companies and Research Institutes for the Years 2016, 2025 & 2030

IV. COMPETITION